U.S. Food and Drug Administration (FDA) idavomereza yoyamba padziko lonse lapansiOral glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. Yopangidwa ndi Novo Nordisk, piritsi la oral semaglutide lakonzedwa kuti liziyambitsa malonda ku United States ku United States.koyambirira kwa Januware 2026.
Deta kuchipatala amasonyeza kuti odwala kulandira25 mg kamodzi patsikuadapeza akuchepetsa kulemera kwa 16.6% pambuyo pa masabata 68, poyerekeza ndi mphamvu ya2.4 mg jakisoni wopangidwa. Chivomerezo chodziwika bwinochi chikuyimira zambiri kuposa chinthu chatsopano - chikuwonetsa kusintha kwakukuluTekinoloje yoperekera mankhwala GLP-1ndikukhazikitsa gawo la gawo latsopano lazatsopano kudera lonse la matenda a metabolic.
01. Kupyolera Mkamwa
Kwa zaka zambiri, kupereka kwapakamwa kwamankhwala a peptide kumawonedwa ngati cholinga chosatheka. Kusakhazikika kwa peptide m'mimba ya asidi komanso kusakwanira kwamatumbo m'matumbo kunabweretsa zopinga zazikulu. Masiku ano, zopinga zimenezo zikuthetsedwa mofulumira.
Kuvomerezedwa kwa oral semaglutide sikupambana kokha koma kutha kwa aokhwima kubweretsa nsanja. Novo Nordisk idachita bwino izi kudzera mukupanga zatsopano, kuphatikiza chowonjezera mayamwidwe.SNAC (sodium N- [8- (2-hydroxybenzoyl) amino] caprylate)mu piritsi.
SNAC imakweza kwakanthawi pH yam'mimba yam'mimba, kuteteza semaglutide ku kuwonongeka kwa enzymatic ndikupangitsa kuyamwa kwa ma transcellular kudutsa m'mimba mucosa. Dongosololi limathandizira kuwonetseredwa kokwanira kwadongosolo kuchokera ku peptide yapakamwa - yomwe idawonedwa ngati zosatheka zaukadaulo - ndikukhazikitsa njira yowopsa yazamoyo zam'kamwa zamtsogolo.
02. Kupumira: Njira Yovuta
Poyerekeza ndi kasamalidwe ka pakamwa, kutulutsa m'mapapo kumapereka njira yolunjika yopita ku systemic circulation. M'zochita, komabe, mapangidwe a peptide omwe amapumira amakumana ndi zovuta zaukadaulo.
Kuyika bwino kwa mapapo kumafunikirakukula kwake kwa tinthu tating'onoting'ono (nthawi zambiri 1-5 μm)kuonetsetsa kuperekedwa kwa alveolar ndi kuyamwa koyenera. Kukwaniritsa izi kumafuna mapangidwe apamwamba komanso njira zopangira zovuta, monga kuyanika kutsitsi ndi uinjiniya wa tinthu.
Zoyeserera zakale zikuwonetsa zovuta. Novo Nordisk mwiniwakeyo adasiya kupanga munthu wopumira wa GLP-1 chifukwa chakutsika kwa bioavailability ndi zotsatira zoyipa zokhudzana ndi chifuwa. Komabe, mundawu ukupitiriza kusinthika. Kafukufuku waposachedwa awonetsa ma semaglutide ufa wowuma wa inhalation formulations nditinthu tating'onoting'ono tomwe timayandikira 60%, zomwe zimatheka chifukwa cha makina okhathamiritsa -owonetsa kuthekera kwatsopano kwa njira yotumizirayi.
03. Kuwonjezeka kwa Chithandizo cha Ultra-Long-Acting GLP-1
Ngakhale njira zapakamwa ndi zokometsedwa zimayang'ana kwambiri kuwongolera kumasuka kwa odwala, njira ina yayikulu yaukadaulo imayang'ana pa.kuchepetsa mlingo wafupipafupi-kuwonjezera jakisoni wamlungu ndi mwezi kapena kotala.
Pakadali pano iyi ndi imodzi mwamabwalo opikisana kwambiri pazamankhwala padziko lonse lapansi R&D. Njira yaikulu imaphatikizapokusintha kwa mankhwala komwe kumakulitsa kwambiri theka la moyo, nthawi zambiri kudzera muukadaulo wa lipidation kapena albin-binding.
Chitsanzo chodziwika bwino ndi PfizerUSD 9.2 biliyoni kupeza Metsera, yomwe cholinga chake ndi kupeza munthu yemwe akhala akuchita kwanthawi yayitali GLP-1MET-097i. Pogwiritsa ntchito fatty acid terminal modification, MET-097i ikuwonetsa lipotitheka la moyo wa pafupifupi maola 380, kuthandizira kuthekera kwakamodzi pamwezi.
Ngakhalenso malingaliro odzikuza kwambiri akutuluka. Ndemanga yaposachedwa yosindikizidwa muJournal of Medicinal Chemistryakuwonetsa kuti njira zatsopano zosinthira ma cell ndi ma cell zitha kuthandizamlingo wa intervals wa miyezi 3 mpaka 6, kutanthauziranso kutsata ndi kusamalira matenda kwa nthawi yayitali.
04. Smart Delivery ndi Digital Tsogolo
Kupanga zatsopano mu chithandizo cha GLP-1 sikungokhala ndi molekyulu yokha. Hardware yobweretsera mankhwala ikusinthanso chimodzimodzi.
Zolembera zama jakisoni anzeru, ma jakisoni odziyimira pawokha, ndi zigamba za microneedleamaphatikizana kwambiri ndi masensa ndi mawonekedwe olumikizana. Zidazi zimatha kutsatira mbiri yamankhwala, kupereka zikumbutso zotsatiridwa, ndi kulunzanitsa deta ndi othandizira azaumoyo. Zikaphatikizidwa ndi mapulatifomu azaumoyo a digito ndi luntha lochita kupanga, ma regimens okhazikika a odwala amatha kukonzedwa bwino kutengera zomwe zikuchitika padziko lapansi.
Kulumikizana ukubiopharmaceuticals, zida zamankhwala, ndi thanzi la digitoikupanga njira yolondola, yokhazikika, komanso yokhazikika yamankhwala osatha.
05. Mapeto
Malinga ndi a Dave Moore, Wachiwiri kwa Purezidenti wa Novo Nordisk U.S. Operations, kukulitsa njira zochizira pakamwa kudzalimbikitsa anthu ambiri kuti aganizire mozama za chithandizo cha GLP-1.
Ndi kukhazikitsidwa kwa mankhwala oyamba a pakamwa a GLP-1, machiritsowa akusintha kuchoka pa jakisoni woyendetsedwa ndi akatswiri kupita kukusankha mankhwala tsiku ndi tsiku. Kuchokera pamapiritsi atsiku ndi tsiku mpaka ma jakisoni apakati pazaka, kuchokera ku zida zanzeru kupita ku njira zosamalira zothandizidwa ndi AI, ukadaulo woperekera umakhala woyendetsa wapakati pakusintha.
Pamapeto pake, kusinthaku sikungokhudza kugonjetsa matenda kokha-komanso kuthandizira amoyo wodziyimira pawokha, wapamwamba kwambiri.
Maumboni
1.https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916473
2.https://ddl-conference.com/ddl2024/conference-papers/semaglutide-powder-for-inhalation-pre-formulation-and-in-vitro-characterization/
3.https://pubmed.ncbi.nlm.nih.gov/39895561/
Nthawi yotumiza: 2026-01-26